Xanthogranulomatous prostatitis is a rare occasion that mimics the prostate cancer in every aspect of clinical diagnosis. These two occasions require totally diverse therapeutics principles. Thus, emphasis should be exerted to distinguish them. The most precise tool to distinguish them is tissues’ evidence. However, another possible overlooking occasion is successive xanthogranulomatous prostatitis after complete remission under androgen deprivation therapy. This case demonstrated one metastatic prostate cancer with initial treatment of androgen deprivation therapy. PSA was suppressed to the lowest and then radical prostatectomy was performed. Hints from the specimen gave complete remission of cancer cell and development of xanthogranulomatous prostatitis.

Background/Objectives: Functional continence and potency outcomes are paramount for the pentafecta of robotic-assisted laparoscopic radical prostatectomy (RARP). We describe a modified approach of the pubovesical complex (PVC)-sparing technique under hypothermia for better continence and potency preservation. Methods: This is a retrospective single-institution case series. Thirty-three PVC-sparing RARP procedures under hypothermia were performed in patients with clinically localized prostate cancer by the same experienced surgeon. The method includes four principles: (1) modified PVC-sparing technique, according to Richard Gaston et al., (2) the use of near-infrared fluorescence technology and indocyanine green to identify the benchmark artery of the neurovascular bundle and blood supply for the PVC, (3) accessory pudendal artery preservation, and (4) hypothermia to reduce tissue edema. Functional outcomes, including continence, potency, and other surgical findings, are presented. This is a feasibility case series, not a comparative or hypothesis-testing study. Results: This study enrolled 33 cases from 15 April 2020 to 31 December 2022. Four patients had positive surgical margins. The urinary continence rate was 100% after Foley removal at a mean of 6.6 days. The potency rate was 74% (17/23) at 6 months and 91.3% (21/23) at 12 months. The inclusion of a small sample of patients from a single hospital and the selection of patient conditions were the study limitations. Conclusions: The modified approach we described is technically feasible, and it can expedite the restoration of urinary function and potency preservation. No severe complications occurred, and patients achieved good oncological outcomes.